Contact

 

Prof. Dr. Claus R. Bartram
Phone: +49 6221 565087

E-mail: cr.bartram@med.uni-heidelberg.de

Cure and care...

 

for families with hereditary syndromes.

Institute of Human Genetics

 

Our group/department has:

  •  been involved in the implementation of a standardized quantitative assessment of MRDbased on immunoglobulin and T-cell receptor gene rearrangements as PCR targets (PCR-MRD), to stratify patients in the AIEOP-BFM ALL 2000 international prospective multicenter study on 2594 childhood ALL patients. The results of the study unambiguously demonstrate that risk stratifi¬cation using immunoglobulin and T-cell receptor gene rearrangements as sensitive MRD-PCR targets is of utmost clinical relevance (Leukemia 2008; Blood 2010)

  • identified relevant loci in a genome-wide association approach for identification of susceptibility variants involved in the etiology of childhood ALL in collaboration with Institute of Cancer Research, Sutton, UK(Blood 2010; Nat Genet 2010)

  • pioneered the development of FISH protocols and the use of the FISH method in diagnostic applications (Blood 2008)

2010 – 2013

  • Conter V.*, Bartram C.R.*, Valsecchi M.G., Schrauder A., Panzer-Grümayer R., Möricke A., Arico M., Zimmermann M., Mann G., De Rossi G., Stanulla M., Locatelli F., Basso G., Niggli F., Barisone E., Henze G., Ludwig W.D., Haas O.A., Cazzaniga G., Koehler R., Silvestri D., Bradtke J., Parasole R., Beier R., van Dongen J.J.M., Masera G., Biondi A., Schrappe M.: Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia (ALL): results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 115, 3206-3214, 2010.

  • Sherborne A.L., Hosking F.J., Prasad R.B., Kumar R., Koehler R., Vijayakrishnan J., Papaemmanuil E., Bartram C.R., Stanulla M., Schrappe M., Gast A., Dobbins S.E., Ma Y., Sheridan E., Taylor M., Kinsey S.E., Lightfoot T., Roman E., Irving J.A.E., Allan J.M., Moorman A.V., Harrison C., Tomlinson I.P., Richards S., Zimmermann M., Szalai C., Semsei A.F., Erdelyi D.J., Krajinovic M., Sinnett D., Healy J., Neira A.G., Kawamata N., Ogawa S., Koeffler H.P., Hemminki K., Greaves M, Houlston R.S.:Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nature Genet. 42, 492-494, 2010.

  • Hemminki K, Müller-Myhsok B, Lichtner P, Engel C, Chen B, Burwinkel B, Försti A, Sutter C, Wappenschmidt B, Hellebrand H, Illig T, Arnold N, Niederacher D, Dworniczak B, Deissler H, Kast K, Gadzicki D, Meitinger T, Wichmann HE, Kiechle M, Bartram CR, Schmutzler RK, Meindl A. Low-risk variants FGFR2, TNRC9 and LSP1 in German familial breast cancer patients. Int J Cancer. 2010, 126(12):2858-62.

  • Gökbuget N., Kneba M., Raff T., Trautmann H., Bartram C.R., Arnold R., Fietkau R., Freund M., Ganser A., Ludwig W.D., Maschmeyer G., Rieder H., Schwartz S., Serve H., Thiel E., Brüggemann M., Hoelzer D.: Adults with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood, 120, 1868-76, 2012.

  • Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R.: TERT promoter mutations in familial and sporadic melanoma. Science 2013; 339(6122):959-61.

  • Deutsche Krebshilfe: Analyse minimaler residueller Leukämiezellen (MRD) bei Kindern mit akuter lymphatischer Leukämie (ALL). 1999 – 2007

  • Deutsche Krebshilfe: Versorgungsoptimierung für Frauen mit einer erblichen Belastung für Brust- und Eierstockkrebs durch ergebnisorientierte Evaluation der präventiven Maßnahmen. 10/2009 – 9/2012

  • NCT: Identification of genetic loci that impart susceptibility to childhood acute lymphoblastic leukemia using genome wide association approach. 2011 – 2013